Clinical Pathological Analysis Of Hodgkin Lymphoma In Pakistan

Abstract

Background: Formerly known as Hodgkin's disease, Hodgkin lymphoma (HL) is caused by germinal centre or post-germinal centre B cells. With an inflammatory backdrop and a small percentage of neoplastic cells (Reed- Sternberg cells and their derivatives), HL has a distinct cellular makeup.

Objectives: The primary goal of the research is to examine the clinic pathological characteristics of Pakistani cases of both classic and non-classic Hodgkin lymphoma.

Study design: A Retrospective hospital study.

Place and duration of study: Department Of  Pathology Watim Medical And Dental College, Rawat  From 05-Jan 2019 To 05-July 2019

Methods: The ethics committee of  Hospital approved this research to be carried out there from January to July 2019. Essentially, ths study was conducted in Watim Medical and Dental College. A woman in her 120s was diagnosed with mixed cellularity Hodgkin lymphoma after presenting with cervical lymphadenopathy and a significant Epstein-Barr virus (EBV) infection. The patient was found to have substantial bone marrow (BM) involvement by Burkitt leukaemia/lymphoma (BL) during the staging workup. Concomitant EBV-related discordant lymphoma (cHL and BL) was diagnosed during the leukemic phase.

Results: The lymph node was subtotally effaced, as shown by a widespread proliferation of lymphoid cells mixed with sporadic histiocytes, plasma cells, and eosinophils, according to a histopathological analysis of the LN. In the reactive backdrop, several big atypical cells were consistent with mummified cells and Hodgkin/Reed-Sternberg cells. The BM examination was carried out as part of the staging workup for HL since the patient's overall health had suddenly become worse. The BM aspirate smear surprisingly revealed infiltration with a medium-sized, regular round nuclei population of leukemic cells (~25%), distributed nuclear chromatin, and profoundly basophilic cytoplasm with significant vacuolation.

Conclusion: It is stated that in patients 38 years of age or older, accurate diagnosis and suitable therapy are critical for composite CHL and B-NHL. The disease subtypes may vary in their natural histories, prognoses, and modes of therapy, hence CHL has to be acknowledged going forward.